Patents Assigned to Jagotec AG
-
Patent number: 10471077Abstract: The present invention provides a medical aerosol suspension formulation of MDI administration, comprising: a) micronized pa-agonist; b) micronized corticosteroid; c) a sib-therapextric quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b), and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.Type: GrantFiled: September 14, 2016Date of Patent: November 12, 2019Assignee: Jagotec AGInventors: Rudi Mueller-Walz, Lise-Marie Fueg
-
Publication number: 20180296468Abstract: In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation.Type: ApplicationFiled: March 21, 2017Publication date: October 18, 2018Applicant: Jagotec AGInventors: Rudi Mueller-Walz, Lise-Marie Fueg
-
Patent number: 10076500Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in gastric fluid, wherein the dosage form is weight biased such that one end is heavier than the other end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the fluid with its heavier end pointing generally downwards and into the fluid.Type: GrantFiled: March 17, 2016Date of Patent: September 18, 2018Assignee: Jagotec AGInventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
-
Patent number: 9895327Abstract: The invention provides a method of producing a highly stable pharmaceutical aerosol suspension formulation suitable for use in a metered dose inhaler, the formulation comprising formoterol fumarate di-hydrate in suspension, a steroid in suspension, a propellant and ethanol, the method comprising the steps of drying the formoterol fumarate di-hydrate to a water content of 4.8 to 4.28%.Type: GrantFiled: November 30, 2015Date of Patent: February 20, 2018Assignee: Jagotec AGInventor: Rudi Mueller-Walz
-
Patent number: 9884021Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: GrantFiled: October 7, 2015Date of Patent: February 6, 2018Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Patent number: 9849097Abstract: A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising pharmaceutically acceptable excipients.Type: GrantFiled: October 8, 2013Date of Patent: December 26, 2017Assignee: Jagotec AGInventors: Alain Nhamias, Nasser Beniou
-
Patent number: 9622980Abstract: The invention provides controlled release oral dosage formulations containing one or more active agents, and methods of using same. In one aspect, the formulation is in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. The core may contain one or more enteric materials or polymeric materials which modulates the release of the active agent.Type: GrantFiled: July 10, 2015Date of Patent: April 18, 2017Assignee: Jagotec AGInventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
-
Patent number: 9314430Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in. gastric fluid, wherein the dosage form is weight biased such that. one end is heavier than the ether end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the: fluid with its heavier end pointing: generally; downwards and into the fluid.Type: GrantFiled: July 4, 2011Date of Patent: April 19, 2016Assignee: Jagotec AGInventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
-
Patent number: 9216157Abstract: Disclosed are tablets having a sandwich-like structure comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and two non-contigous outer layers comprising antiadhesion excipients and compression adjuvants preventing the adhesion to the punches of the tabletting machine and possibly active ingredients which are the same as or different from those present in the inner layer. Said tablets are obtainable by direct compression of mixtures or granulates of the various components of each layer.Type: GrantFiled: January 20, 2004Date of Patent: December 22, 2015Assignee: Jagotec AGInventor: Alberto Salini
-
Patent number: 9186332Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: GrantFiled: December 13, 2012Date of Patent: November 17, 2015Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Patent number: 9101544Abstract: Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULARĀ®). The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers.Type: GrantFiled: August 29, 2007Date of Patent: August 11, 2015Assignee: Jagotec AGInventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
-
Patent number: 9040085Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: GrantFiled: July 11, 2014Date of Patent: May 26, 2015Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Patent number: 8980363Abstract: The present invention provides a method and apparatus for positioning the core of the compression coated tablet in manufacturing techniques for the production of such tablets.Type: GrantFiled: February 15, 2008Date of Patent: March 17, 2015Assignee: Jagotec AGInventors: Pascal Grenier, Guy Vergnault
-
Patent number: 8927028Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.Type: GrantFiled: December 15, 2005Date of Patent: January 6, 2015Assignee: Jagotec AGInventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias
-
Patent number: 8927608Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.Type: GrantFiled: February 16, 2011Date of Patent: January 6, 2015Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier
-
Patent number: 8877251Abstract: The present invention relates to methods of making a powder for inhalation comprising a first step of mixing particles of a force-controlling agent selected from the group consisting of phospholipids, titanium dioxide, aluminum dioxide, silicon dioxide, starch, and salts of fatty acids, with particles of one or more pharmacologically active materials, wherein the mixing is achieved by one or more of the processes of sieving, mixing or blending, and wherein the mixing results in the particles of the force-controlling agent being disposed on the surface of the particles of the one or more pharmacologically active materials as either a particulate coating or as a continuous or discontinuous film.Type: GrantFiled: September 5, 2012Date of Patent: November 4, 2014Assignee: Jagotec AGInventor: Rudi Mueller-Walz
-
Publication number: 20140314684Abstract: The present invention provides a process for making a stabilized medical aerosol suspension formulation for administration by a pressurized metered dose inhaler.Type: ApplicationFiled: May 16, 2014Publication date: October 23, 2014Applicant: JAGOTEC AGInventors: Rudi Mueller-Walz, Lise-Marie Fueg
-
Publication number: 20140243296Abstract: A treatment regimen and dosage form comprising ritonavir and darunavir and their use in the treatment of HIV infection.Type: ApplicationFiled: October 5, 2012Publication date: August 28, 2014Applicant: JAGOTEC AGInventors: Pascal Grenier, Guy Vergnault, Patricia Ibarra
-
Publication number: 20140150788Abstract: The present invention provides dry powder formulations for inhalation having improved moisture resistance such that the powders maintain a high fine particle dosage or fine particle fraction following storage under relatively extreme temperature and humidity conditions.Type: ApplicationFiled: November 22, 2013Publication date: June 5, 2014Applicant: Jagotec AGInventors: Manfred Keller, Rudi Mueller-Walz
-
Patent number: 8703202Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: July 24, 2006Date of Patent: April 22, 2014Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadhesh, Robert A. Snow, Pol-Henri Guivarc'h